Senp1 Protein Sumo Specific Peptidase 1 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
| SENP1 Protein | |
|---|---|
| Protein Name | SUMO-specific protease 1 |
| Gene Symbol | SENP1 |
| NCBI Gene ID | 10687 |
| UniProt ID | Q9Y2X0 |
| MW | 71 kDa |
| Subcellular Location | Nucleus, Cytoplasm |
SENP1 (SUMO-specific protease 1) is a member of the sentrin/SUMO-specific protease family that catalyzes the deconjugation of SUMO (Small Ubiquitin-like Modifier) proteins from their targets[1]. SENP1 plays critical roles in regulating protein function through SUMOylation, a reversible post-translational modification that controls protein localization, stability, activity, and protein-protein interactions[2]. Dysregulation of SENP1 has been implicated in cancer, cardiovascular disease, and neurodegenerative disorders including Alzheimer's disease (AD) and Parkinson's disease (PD)[3].
SENP1 catalyzes both SUMO precursor processing and deconjugation:
SENP1 is primarily nuclear and regulates key nuclear processes:
The study of Senp1 Protein Sumo Specific Peptidase 1 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Hay RT, et al. (2007). SUMO: a history of modification. Molecular Cell. 28: 1-13. ↩︎
Geiss-Friedlander R, et al. (2007). Concepts in sumoylation: a decade on. Nature Reviews Molecular Cell Biology. 8: 947-956. ↩︎
Wu Y, et al. (2019). SENP1 in neurodegeneration: friend or foe? Frontiers in Neuroscience. 13: 1172. ↩︎
Luo J, et al. (2012). SUMOylation at the crossroads of autophagy and neurodegeneration. Journal of Molecular Neuroscience. 48: 177-183. ↩︎
Kim JM, et al. (2017). alpha-Synuclein SUMOylation and Parkinson's disease. Movement Disorders. 32: 1602-1614. ↩︎
Tatham MH, et al. (2009). Systematic identification of SUMO2/3-modified proteins in response to DNA damage. Journal of Proteomics. 72: 113-121. ↩︎